2021 KyPQC Fall Meeting

2021 KyPQC Recordings - Maternal Health Equity in Vulnerable Populations - Morbidity, Mortality and Racial Disparities: What Can We Do?

Activity Details
  • Credit Amounts:
    • CME: 1.75
    • CNE: 1.75
  • Cost: Free
  • Release: Oct 20, 2021
  • Expires: Oct 20, 2024
  • Estimated Time to Complete:
    1 Hour(s)  45 Minutes
  • Average User Rating:
    ( Ratings)

This is a recording from the live 3rd Annual KyPQC Conference, dated October 20-21, 2021. If you claimed credit for this session at the live meeting, you should not claim credit for this module. 


Haywood L.  Brown Haywood L. Brown, MD
Senior Associate Vice President Of Academic Affairs, USF Health
Vice Dean Of Faculty Affairs
The Morsani College Of Medicine
Tampa, Florida

Dena Goffman Dena Goffman, MD
Chief of Obstetrics, Professor and Vice Chair for Quality and Patient Safety
Obstetrics and Gynecology
Sloane Hospital for Women at New York-Presbyterian Hospital and Columbia University Medical Center
Associate Chief Quality Officer, Obstetrics
New York Presbyterian Health System
New York, New York

Needs Statement

The U.S. has the worst rate of maternal deaths in the developed world, and 60 percent are preventable. The death of a neonatal nurse in the hospital where she worked illustrates a profound disparity: The health care system focuses on babies but often ignores their mothers.

Target Audience

Healthcare professionals interested in successful quality improvement initiatives that could be implemented in delivery hospitals.


Upon completion of this activity, participants will be able to:
1. Discuss health inequity and the impact on maternal health disparities
2. Emphasize the impact of racial and economic biases on maternal outcomes for individuals from marginalized populations at the clinical, operational and system levels
3. Discuss health policy implications in support of quality, innovation and partnerships in maternal care that can potentially dismantle health inequities
4. Recognize current disparities in severe maternal morbidity and mortality
5. Identify practical opportunities to begin to address


In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This enduring material is designated for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.75 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. 

Haywood Brown, MD faculty for this educational event, is on the Advisory Board for Merck Global Health; medical advisor for Carrier Screening Coalition; consultant for Myriad; & consultant medical for Hologic.

Dena Goffman, MD, faculty for this educational event, is on the advisory board of Roche Preeclampsia and on the safety Council for Cooper Surgical Obstetrical.

All of the relevant financial relationships listed for these individual have been mitigated. No other speakers, planners, or content reviewers have any relevant financial relationships to disclose. 

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


KyPQC is Supported by Cooperative Agreement number 2 NU17CE924971, funded by the Centers for Disease Control and Prevention (CDC).